Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer
Author:
Open Access
- 23 June 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 35 (7) , 365-374
Abstract
A radical prostatectomy has been established as one of the standard management options for localized prostate cancer. However, a substantial proportion of patients who undergo a radical prostatectomy develop prostate-specific antigen (PSA) recurrence which is commonly defined as a PSA cut-off point value of 0.2 ng/ml. Although the management of PSA recurrence after radical prostatectomy may depend on the site of recurrence, it is quite difficult to identify the recurrent lesion accurately based on the currently available imaging technology. Patients who have surgical margin involvement or a Gleason score ≤7 based on the radical prostatectomy specimens, who do not have nodal or seminal vesicle involvement, and who develop a PSA recurrence >1–2 years after surgery with a doubling time of >1 year, and whose pre-treatment PSA is <1.0–1.5 ng/ml are considered to benefit from local treatment with at least 64 Gy of salvage radiotherapy. Patients with different characteristics are considered to have distant metastases or both local lesions and distant metastases, and thus may be candidates for hormonal manipulation rather than radiotherapy. Since local recurrent lesions are considered to be quite small at the early stage of PSA recurrence, hormonal manipulation may be sufficient to prevent disease progression instead of radiotherapy. However, the optimal type and timing of hormonal manipulation remain to be elucidated. As a result, no consensus regarding the treatment for PSA recurrence after radical prostatectomy has yet been reached.Keywords
This publication has 91 references indexed in Scilit:
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 1997
- Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostateBritish Journal of Urology, 1997
- Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancerUrology, 1996
- Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate CancerJournal of Urology, 1994
- The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical ProstatectomyJournal of Urology, 1994
- Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 YearsJournal of Urology, 1994
- 5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate CancerJournal of Urology, 1994
- Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated PatientsJournal of Urology, 1989
- Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical ProstatectomyJournal of Urology, 1988